Valeant Shows Peril of Fantasy Numbers

Gretchen Morgenson New York Times November 1, 2015

Investors often say they learn more from investment losers than from winners. That suggests that Valeant, the beleaguered pharmaceutical company whose market value has fallen by almost $60 billion since August, offers a bounty of teaching moments.